Betty joined Auron Therapeutics in January 2021. She is a data-driven and motivated scientist with 15+ years of experience building and leading biochemistry capabilities. Betty’s interest and expertise include advancing small molecules from various hit finding approaches (including DNA-encoded library screening and machine learning) to IND filing and developing innovative assays to interrogate new modalities and their MoA. Prior to joining Auron, she worked at Civetta Therapeutics, Kymera Therapeutics, X-Chem Pharmaceuticals, H3 Biomedicine, and Galenea Corporation.
Betty has a PhD in Biological Chemistry and Molecular Pharmacology from Harvard University. Prior to her graduate studies, she completed a 4-year program at Brandeis University where she received a M.S. in Molecular and Cell Biology and bachelor’s degrees in Biochemistry, Biology, and French Language and Literature.
Betty has an avid interest in fitness. She enjoys the technical and cardio conditioning aspects of boxing/lifting and running/cycling, respectively, and relishes in collecting her training data to track progress and performance.